Alpha Lipoic Acid (ALA) for Neuroprotection

Alpha lipoic acid is one of the few antioxidants that crosses the blood-brain barrier readily and works in both aqueous and lipid environments, which is why it keeps appearing in neuroprotection research. Its strongest clinical evidence, though, is peripheral rather than central: diabetic peripheral neuropathy, where trials show reduced burning, numbness and paraesthesia. That is genuine neuroprotection in the sense most readers care about — a nerve symptom improved by a supplement — but it is not the same as protecting the brain from cognitive decline.

For central endpoints the picture is thinner. Small trials in Alzheimer's disease and multiple sclerosis have reported slowed decline or reduced brain atrophy, but sample sizes are small and the results have not been replicated at scale. A reasonable expectation: worthwhile if you have diabetic neuropathy, plausible but unproven for broader brain protection.

ALA is amphipathic and small enough to enter the central nervous system, where it and its reduced form dihydrolipoic acid neutralise reactive oxygen species directly and regenerate glutathione, vitamin C and vitamin E. Neural tissue is unusually vulnerable to oxidative damage because of its high lipid content and oxygen consumption, so a recycling antioxidant has a plausible role.

In diabetic neuropathy specifically, ALA reduces flux through the polyol pathway and inhibits advanced glycation end-product formation, both of which damage peripheral nerves in hyperglycaemia. It also improves endoneurial blood flow, addressing the microvascular component of nerve injury. Additional mechanisms relevant to central protection include metal chelation — iron and copper accumulation contributes to oxidative injury in neurodegeneration — and Nrf2 pathway activation, which upregulates the cell's own antioxidant enzymes rather than supplying antioxidant capacity directly.

600 mg daily is the neuropathy standard and the dose with the best benefit-to-tolerability ratio; higher doses increase nausea without clearly improving results. Take it fasted, since food reduces absorption by roughly 30 percent.

The diabetic neuropathy literature is the substantial part of this evidence base. Randomised trials of intravenous ALA show clear short-term symptom reduction, and oral trials at 600 mg daily report improvements in neuropathic symptom scores over three to six months, with meta-analyses broadly supportive though noting heterogeneity and industry sponsorship. Effects on objective nerve conduction measures are more modest than effects on symptoms. Central neuroprotection is a different evidentiary tier: small open-label and pilot randomised work in Alzheimer's disease and multiple sclerosis has reported slowed progression or reduced brain atrophy, but the trials are too small to be conclusive. No pair-specific studies are linked to this page yet, so no study list is displayed and no citations are inferred.

At 600 mg daily ALA is well tolerated, with nausea, reflux, a metallic taste and occasional skin rash the usual reports — mostly dose-related and improved by splitting doses. Very large accidental overdoses have caused serious toxicity, so keep it away from children.

The interactions worth knowing are additive glucose lowering, metal chelation affecting mineral and thyroid medication absorption, and thiamine depletion — the last being particularly relevant when the reason for taking ALA is nerve symptoms.